Stay updated on Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A site-wide banner announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T16:11:38.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.1 to v3.7.2 while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T20:42:11.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T20:27:59.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the study content and preventing access to the ClinicalTrials.gov record.
    Difference
    0.5%
    Check dated 2026-09-27T19:56:12.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    A 403 Forbidden page is now displayed, indicating access is blocked; the study content and navigation blocks that normally present trial details are replaced by a standard error view.
    Difference
    16%
    Check dated 2026-09-20T20:43:26.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    The page now states the study has 199 locations and removes several previously listed sites. The eligibility language is refined to specify TP53 wild-type status by central NGS for histologically confirmed endometrial cancer.
    Difference
    0.5%
    Check dated 2026-08-30T21:54:41.000Z thumbnail image

Stay in the know with updates to Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page.